4DMedical's CMS Reimbursement Announcement

4DMedical Limited (ASX: $4DX) has received approval from the American Medical Association (AMA) CPT Editorial Panel for the reimbursement of its CT LVASTM technology in the U.S. The approval allows 4DMedical to utilize two existing Category III CPT codes for the reimbursement of CT LVASTM, with a benchmark payment level set for hospital outpatient procedures, effective immediately.

Executive Commentary on CMS Reimbursement

I am very excited by this progress in the commercialization of our technology, and the positive impact this CPT code and associated reimbursement will have upon doctors and their patients. An identified Medicare reimbursement of US$650.50 per scan provides direct access to CT LVASTM for the 66 million Americans enrolled in Medicare. The routine use of chest CT in the clinical work up of respiratory patients, combined with the recognized value of our scan, makes the AMA's decision one of the most significant breakthroughs to date in our history. Furthermore, I believe this decision helps to establish the appropriate pricing of our technology within the VA. I am excited to note that this news comes less than 6 months following the FDA clearance of CT LVAST, demonstrating growing strength in our team and our reputation with key organizations such as the AMA and associated medical societies. This bodes well for continued success with reimbursement of future products such as IQ-UIP and CT:VQ, both expected to be filed with the FDA in 2024.

Summary of 4DMedical's CMS Reimbursement Announcement

4DMedical Limited (ASX: $4DX) has achieved a significant milestone with the inclusion of its CT LVASTM technology to existing Category III Current Procedural Terminology (CPT) codes, allowing access to the U.S. Centers for Medicare & Medicaid Services (CMS) annual, final payment rates for hospital outpatient-based services. The approval provides widened access to CT LVASTM for patients at Medicare-funded facilities, with a benchmark payment level set for hospital outpatient procedures, serving as a guide for private health insurers in determining their pricing levels. This decision is considered a significant breakthrough in 4DMedical's history and is expected to pave the way for continued success with reimbursement of future products. The company's CEO, Andreas Fouras, expressed excitement about the decision and its potential impact on the commercialization of their technology, highlighting the growing strength of the team and the positive reputation with key organizations. With the recent FDA clearance of CT LVAST, the company is optimistic about the future success of its upcoming products, demonstrating a positive outlook for 4DMedical's corporate strategy and growth.